Research Blog
Expert analysis, breaking news, and informed commentary on retatrutide research, clinical trial updates, conference presentations, and regulatory milestones.
Next-Gen Obesity Drugs Compared: The 2026 Pipeline
Comparing retatrutide, orforglipron, amycretin, MariTide, survodutide, and VK2735 — mechanisms, efficacy data, and timelines as of April 2026.
Diet and Nutrition on Retatrutide: A Practical Guide
What to eat on retatrutide, how much protein you need, hydration strategies, and micronutrients to watch — based on clinical trial data.
Retatrutide Drug Interactions: What Clinicians Should Know
Analysis of potential retatrutide drug interactions based on GLP-1 class effects, including oral contraceptives, metformin, insulin, and anticoagulants.
Retatrutide and Hair Loss: What the Evidence Actually Says
Is retatrutide causing hair loss? A look at telogen effluvium during rapid weight loss, GLP-1 trial data, and what you can do about it.
Retatrutide and Sleep Apnea: What the TRIUMPH Data May Show
Clinical analysis of retatrutide's potential for obstructive sleep apnea based on TRIUMPH-2 protocols, tirzepatide precedent, and weight-loss-driven mechanisms.
Retatrutide and Weight Regain: What Happens When You Stop
Analysis of weight regain risk after stopping GLP-1 therapies and what retatrutide's TRIUMPH program tells us about long-term maintenance dosing.
Why You Can't Safely Buy Retatrutide Online: Gray Market Risks Explained
Retatrutide is widely available from online 'research peptide' vendors, but these products carry significant safety risks. This article explains why gray-market retatrutide is dangerous, what FDA enforcement actions have occurred, and why clinical-grade manufacturing matters.
What Will Retatrutide Cost? Analyzing Eli Lilly's Pricing Signals
No price announced for retatrutide, but tirzepatide pricing, the biologic lawsuit, analyst projections, and Lilly's $3.5B plant offer clues on future cost.
Retatrutide in the UK and Europe: Regulatory Pathway and Expected Timeline
Retatrutide is not approved in the UK or EU as of 2026. Covers MHRA and EMA pathways, expected timelines (late 2028 UK, 2029 EU), and NICE assessment.
Retatrutide Dose Escalation Explained: Why Starting Low Matters
Understanding dose escalation in retatrutide and other GLP-1 class drugs — how gradual titration improves tolerability, what the Phase 2 trial revealed, and implications for clinical practice.
Retatrutide and Dysesthesia: What the Phase 3 Data Actually Shows
A clinical analysis of the dysesthesia signal observed in retatrutide's TRIUMPH-4 Phase 3 trial — incidence rates, severity, potential mechanisms, and what it means for regulatory review.
Retatrutide and Liver Fat: The MASLD Data That Changed the Conversation
An analysis of retatrutide's liver fat reduction data from Phase 2 imaging substudies, the role of glucagon receptor agonism in hepatic lipid metabolism, and the implications for MASLD/MASH as a therapeutic indication.
Does Retatrutide Preserve Muscle? What the Body Composition Data Shows
An evidence-based analysis of retatrutide's Phase 2 body composition substudy, examining the ratio of fat mass to lean mass loss and what it means for clinical outcomes.
How Phase 3 Changed Retatrutide's Dosing Protocol — and Why It Matters
An analysis of the key differences between retatrutide's Phase 2 and Phase 3 dose escalation protocols, the clinical rationale behind the changes, and what they signal about Eli Lilly's regulatory strategy.
The Future of Obesity Pharmacotherapy: From Single Agonists to Combination Approaches
Where obesity treatment is headed — the evolution from GLP-1 monotherapy to multi-receptor agonists and combination strategies, and where retatrutide fits in the expanding pipeline.
Liver Fat Reduction With Retatrutide: Why the Phase 2 Data Are Significant
An in-depth analysis of retatrutide's approximately 82% liver fat reduction in Phase 2 — what it means for MASLD treatment, why glucagon receptor agonism drives the effect, and how it compares to other therapeutic approaches.
Putting 28.7% Weight Loss in Context: What Retatrutide's Numbers Mean
What does 28.7% mean body weight loss actually look like in clinical practice? Contextualizing retatrutide Phase 3 data against bariatric surgery, lifestyle intervention, and responder analysis.
Retatrutide FDA Approval Timeline: When Will Retatrutide Be Available?
Retatrutide FDA approval timeline: Phase 3 TRIUMPH status, TRIUMPH-4 results (-28.7% weight loss), NDA filing late 2026, and availability projections for 2027-2028.
Retatrutide vs. Mounjaro: Two Drugs, One Company, Different Targets
How Eli Lilly is developing both tirzepatide (Mounjaro/Zepbound) and retatrutide — examining dual vs. triple agonism, clinical differentiation, and portfolio strategy.
Retatrutide vs. Wegovy: What the Data Actually Shows
A cross-trial comparison of retatrutide and semaglutide 2.4 mg (Wegovy), examining weight loss efficacy, mechanism differences, and the limitations of indirect comparisons.
Retatrutide Side Effects: What Clinical Studies Actually Show
A factual, evidence-based summary of adverse events reported in retatrutide Phase 1 and Phase 2 clinical trials — gastrointestinal effects, dose-dependent patterns, discontinuation rates, and how they compare to other incretin-based therapies.
The TRIUMPH Phase 3 Program: Everything We Know
A comprehensive guide to Eli Lilly's TRIUMPH clinical trial program for retatrutide — individual trial designs, enrollment targets, primary endpoints, expected timelines, and what it all means for potential regulatory approval.
Why the Glucagon Receptor Matters: The Third Component of Triple Agonism
An analysis of why adding glucagon receptor agonism to GLP-1 and GIP activity makes retatrutide mechanistically distinct — and how glucagon's effects on energy expenditure, liver fat metabolism, and thermogenesis may drive superior clinical outcomes.
What Phase 3 Means: Understanding the TRIUMPH Program
An explanation of what Phase 3 clinical trials represent in drug development, what the TRIUMPH program is designed to answer, and what stakeholders should expect from retatrutide's pivotal trials.
Why Triple Agonism Matters: The Next Frontier in Metabolic Medicine
An analysis of why targeting three metabolic hormone receptors simultaneously represents a meaningful advancement over single and dual agonist approaches, and what it means for the future of obesity and diabetes treatment.
Retatrutide in the Context of the GLP-1 Revolution
How retatrutide fits into the broader GLP-1 revolution that is transforming metabolic medicine, and what the competitive landscape means for the future of obesity and diabetes treatment.
Breaking Down the Phase 2 Obesity Results: What the Numbers Actually Mean
A detailed analysis of retatrutide's Phase 2 obesity trial data published in the New England Journal of Medicine, explaining what the key endpoints and results signify for the field.
How to Read Clinical Trial Data: A Practical Guide for Non-Scientists
An educational guide explaining how to interpret clinical trial results, including endpoints, statistical significance, effect sizes, and common pitfalls, using examples from metabolic medicine research.